Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 15Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Carcinoid Tumor 2Serotonin Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Disease 1Digestive System Neuroendocrine Tumor G1 1Colorectal Neoplasms 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenoma 1Acromegaly 1

Interventions

pasireotide 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hypoglycemia × NET × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡